0001493152-22-033543.txt : 20221123 0001493152-22-033543.hdr.sgml : 20221123 20221123160535 ACCESSION NUMBER: 0001493152-22-033543 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20221123 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221123 DATE AS OF CHANGE: 20221123 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PALISADE BIO, INC. CENTRAL INDEX KEY: 0001357459 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 522007292 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33672 FILM NUMBER: 221416366 BUSINESS ADDRESS: STREET 1: 7750 EL CAMINO REAL, SUITE 5200 CITY: CARLSBAD STATE: CA ZIP: 92009 BUSINESS PHONE: (858) 704-4900 MAIL ADDRESS: STREET 1: 7750 EL CAMINO REAL, SUITE 5200 CITY: CARLSBAD STATE: CA ZIP: 92009 FORMER COMPANY: FORMER CONFORMED NAME: Seneca Biopharma, Inc. DATE OF NAME CHANGE: 20200127 FORMER COMPANY: FORMER CONFORMED NAME: Neuralstem, Inc. DATE OF NAME CHANGE: 20060324 8-K 1 form8-k.htm
0001357459 false 0001357459 2022-11-23 2022-11-23 iso4217:USD xbrli:shares iso4217:USD xbrli:shares











Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 23, 2022 (November 17, 2022)



(Exact name of Registrant as Specified in Its Charter)


Delaware   001-33672   52-2007292

(State or Other Jurisdiction

of Incorporation)



File Number)


(IRS Employer

Identification No.)


7750 El Camino Real

Suite 5200

Carlsbad, California   92009
(Address of Principal Executive Offices)   (Zip Code)


Registrant’s telephone number, including area code: (858) 704-4900



(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class  




Name of each exchange

on which registered

Common Stock, par value $0.01 per share   PALI   Nasdaq Capital Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐







Item 5.02. Departure of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers


Appointment of Dr. Herbert Slade as Chief Medical Officer


On November 17, 2022, the Board of Directors of Palisade Bio, Inc. (“Company”) appointed Herbert B. Slade, MD FAAAAI, to serve as the Company’s chief medical officer. Dr. Slade will serve this role as a consultant on a part time basis and will be compensated $240,000 per annum. Dr. Slade has previously been providing consulting services to the Company since May of 2022. The Company anticipates entering into an amended and restated consulting agreement with Dr. Slade. Dr. Slade’s consulting arrangement does not provide for any severance or other termination-based benefits upon termination or resignation.


There are no family relationships between Dr. Slade and any of the directors or officers of the Company.


Dr. Slade, age 68, has over 25 years of leadership experience in the pharmaceutical and medical device industries, demonstrating execution of regulatory negotiations with the U.S. Food and Drug Administration and European Medicines Agency, and the design, conduct, and reporting of clinical programs. Since 2007, Dr. Slade has been serving as the Adjunct Clinical Assistant Professor of the Department of Pediatrics at the Texas College of Osteopathic Medicine. Since 2018, he has also been serving as the treasurer and member of the Board of Directors of the Wound Healing Society, a 501(c)3 organization. He serves as President and Managing Director of Chisholm Clinical Research Services, a Texas limited liability company, where he provides assistance with the clinical development of promising new products for 6 client companies in the US and EU. From 2012 to 2016, Dr. Slade served as Chief Medical Officer and then Sr. Vice President of Research and Development in the Advanced Wound Management department of Smith and Nephew, plc, where he was responsible for restructuring 3 strategic business R&D departments and two clinical groups into a single worldwide R&D organization. Prior to that, from 2006 to 2012, Dr. Slade served as Chief Medical Officer and Sr. Vice President at DFB Pharmaceuticals, a private Texas company, until it was acquired by Smith & Nephew in 2012. Dr. Slade has additionally served in various chief medical officer and other senior positions of various private and public pharmaceutical companies throughout his career. Dr. Slade received a bachelor’s degree from Hamilton College in Clinton, NY, a Medical Degree from State University of New York in Syracuse, NY, a Pediatrics category PL-1 from State University of New York, a Pediatrics category PL-2 from C.S. Mott Children’s Hospital in Ann Arbor, MI, and a fellowship in Basic and Clinical Immunology from the University of Michigan in Ann Arbor, MI.


On November 18, 2022, the Company issued a press release announcing Dr. Slade’s appointment, which is attached to this report as Exhibit 99.01.


Item 9.01 Financial Statement and Exhibits.





Press Release Dated November 18, 2022

104   Cover Page Interactive Data File (embedded within the Inline XBRL document)







Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.


Date: November 23, 2022 Palisade Bio, Inc.
      /s/ J.D. Finley
    By: J.D. Finley
      Interim Chief Executive Officer



EX-99.01 2 ex99-01.htm


Exhibit 99.01



Palisade Bio Appoints Herbert B. Slade, MD, FAAAAI as Chief Medical Officer


Established academic and corporate executive with proven track record leading large, multinational organizations across the pharmaceutical and medical device industries


Well-versed with LB1148 - serving as recent expert clinical advisor to Palisade Bio


Carlsbad, CA – November 18, 2022 -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the appointment of Herbert B. Slade, MD, FAAAAI as Chief Medical Officer of Palisade Bio.


Dr. Slade is a proven medical and regulatory professional with over 25 years of leadership experience in the pharmaceutical and medical device industries. Over the course of his career, he has demonstrated execution of regulatory negotiations with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) and the design, conduct and reporting of clinical programs.


“Over the past six months Dr. Slade has provided important input and guidance in advancing the development of LB1148 as a clinical advisor to the Company. We firmly believe his appointment as Chief Medical Officer will be a natural transition, and we are very pleased to welcome him to the executive leadership team. Throughout his career, he has amassed valuable expertise across the healthcare industry and academia and has developed a deep-rooted, respected skillset in research and development that we believe will be critical as we move our development programs forward. We will continue to leverage Dr. Slade’s perspective and leadership as we work to unlock the full potential of the Company and LB1148 for all stakeholders,” commented JD Finley, interim CEO of Palisade Bio.


“There remains a significant unmet need when it comes to addressing acute and chronic gastrointestinal post-surgical complications and the serious risks that come with them. I believe that the demonstrated mechanism to protect intestinal barrier health and the data seen to date well position LB1148 to become a potential standard of care, and I am dedicated to further advancing its development. With the prioritization on the prevention of adhesions program, I believe we have the potential to offer millions of patients an important therapeutic option and provide a much-needed benefit. Having closely worked with the Palisade Bio team as a clinical advisor for LB1148 over the past several months, I am excited to continue building on the progress made and look forward to bringing its development successfully across the finish line,” added Dr. Slade.


Dr. Slade currently serves as the Adjunct Clinical Associate Professor, Dept. of Pediatrics, Texas College of Osteopathic Medicine, UNTHSC and as Treasurer and member of the Board of Directors of The Wound Healing Society. He joins Palisade Bio having most recently served as the President and Managing Director of Chisholm Clinical Research Services, LLC (CCRS) where he provided assistance with clinical testing and development of promising new products for 11 client companies in seven countries. Prior to CCRS, Dr. Slade served as Chief Scientific and Medical Officer, Advanced Wound Management of Smith and Nephew plc before transitioning to Sr. Vice President, Research & Development where he was responsible for restructuring three strategic business unit R&D departments and two clinical groups into a single worldwide R&D organization, adding post-marketing surveillance. Prior to that he served as Chief Medical Officer and Senior Vice President at DFB Pharmaceuticals until it was acquired by Smith & Nephew in 2012. Additional career appointments include Chief Medical Officer of 3M Pharmaceuticals where he was responsible for all Medical, Clinical Research, Biometrics, Data Management and Pharmacovigilance personnel worldwide for 12 years. Dr. Slade also was afforded the unique opportunity to work at Rhône-Poulenc Rorer (RPR) with the prestigious Dr. Jonas Salk, as the principal physician and clinical immunologist on the Salk HIV Immunogen project. During that time, he assisted Dr. Salk on a wide range of program issues including the scientific validity of a therapeutic vaccine (now termed Theracines or Pharmacines), and the importance of the Th1/Th2 concept.





Dr. Slade has authored or co-authored over 100 publications. He has held academic positions at a number of universities including University of Michigan Medical School, Cornell University Medical College, University of North Texas Health Science Center, and University of Pennsylvania Medical School. Dr. Slade received his undergraduate degree in biology from Hamilton College and his M.D. from State University of New York Upstate Medical University in Syracuse, New York. He completed post doctorate work at S.U.N.Y. Upstate Medical Center and C.S. Mott Children’s Hospital and completed his fellowship at the University of Michigan.


About Palisade Bio


Palisade Bio is a biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The Company utilizes over three decades of research and established science that links the role of intestinal barrier biology and human disease to develop novel therapeutics that target and improve the integrity of the intestinal barrier.


The Company’s lead program, LB1148, is a broad-spectrum serine protease inhibitor which acts to neutralize digestive enzymes, potentially reducing intestinal damage. In clinical studies, LB1148 has demonstrated positive results in accelerating the time to return of postoperative bowel function, and reduced the incidence and severity of post-surgical abdominal adhesions. LB1148 is currently being evaluated in a Phase 2 study to evaluate return of gastrointestinal function, post-operative ileus and intra-abdominal adhesions in subjects undergoing elective bowel resection (PROFILE).


The Company believes that addressing the disruption of the intestinal barrier can fundamentally change the way diseases are treated and establish new standards of patient care. For more information, please go to www.palisadebio.com.


Forward Looking Statements


This communication contains “forward-looking” statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: progress of studies, including opening additional clinical trial sites, timing of results or data, progress and completion of patient enrollment, including timing thereof and the Company’s co-development partner’s expectation to complete enrollment; regulatory progress and strategy, including potential registration and commercialization of LB1148; the extent of the cash runway; the closing of the underwritten public offering; and expected proceeds from financings. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon the Company’s current expectations. Forward-looking statements involve risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the Company’s ability to advance its clinical programs, the uncertain and time-consuming regulatory approval process; the Company’s ability to achieve additional financing to fund future operations and the Company’s ability to comply with the continued listing requirements for Nasdaq. Additional risks and uncertainties can be found in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the Securities and Exchange Commission (“SEC”) on March 17, 2022, Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, filed with the SEC on November 14, 2022, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.


Investor Relations Contact



Jenene Thomas




Source: Palisade Bio



GRAPHIC 3 ex99-01_001.jpg begin 644 ex99-01_001.jpg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end EX-101.SCH 4 pali-20221123.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 pali-20221123_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 pali-20221123_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Nov. 23, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 23, 2022
Entity File Number 001-33672
Entity Registrant Name PALISADE BIO, INC.
Entity Central Index Key 0001357459
Entity Tax Identification Number 52-2007292
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 7750 El Camino Real
Entity Address, Address Line Two Suite 5200
Entity Address, City or Town Carlsbad
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92009
City Area Code (858)
Local Phone Number 704-4900
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.01 per share
Trading Symbol PALI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001357459 2022-11-23 2022-11-23 iso4217:USD shares iso4217:USD shares 0001357459 false 8-K 2022-11-23 PALISADE BIO, INC. DE 001-33672 52-2007292 7750 El Camino Real Suite 5200 Carlsbad CA 92009 (858) 704-4900 false false false false Common Stock, par value $0.01 per share PALI NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://palisadebio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-01.htm pali-20221123.xsd pali-20221123_lab.xml pali-20221123_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "pali-20221123_lab.xml" ] }, "presentationLink": { "local": [ "pali-20221123_pre.xml" ] }, "schema": { "local": [ "pali-20221123.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "PALI", "nsuri": "http://palisadebio.com/20221123", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-11-23to2022-11-23", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://palisadebio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-11-23to2022-11-23", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://palisadebio.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001493152-22-033543-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-033543-xbrl.zip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end